Cryobiopsy for diagnosing mediastinal conditions in Sweden

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study evaluates the effectiveness of Endobronchial UltraSound TransBronchial Mediastinal CryoBiopsy (EBUS TBMCB) in diagnosing mediastinal lymphadenopathy, lung cancer, sarcoidosis, lymphoma, and tuberculosis. Participants will undergo EBUS TBNA and EBUS TBMCB procedures, with their biopsy samples compared to assess the diagnostic yield of each method. The study aims to determine how many biopsies are necessary to achieve a definitive diagnosis and to evaluate the added value of combining EBUS TBMCB with EBUS TBNA. Follow-up assessments will occur four weeks post-procedure to monitor for any complications.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Mediastinal lymphadenopathy with a diameter greater than 1 cm.
* Indication for assessment and sampling according to clinical praxis
* Age \> 18 years
* Patients consent to participate in the study.

Exclusion Criteria:

* Hemodynamically instable patient
* Myocardial infarction in the last six weeks prior to participating in the study.
* Life threatening arrythmia
* Respiratory failure and inadequate blood oxygenation despite oxygen supply.
* Tracheal obstruction of high grade.
* High bleeding risk
* Patient not willing to participate in the study
* Patient not speaking swedish and needing translator during the procedure

Where it's running

• Respiratory medicine and allergy department, Skåne University Hospital
  Lund, Sweden Recruiting
• Norrlands universitetssjukhus
  Umeå, Sweden Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• 18F-G1 PET/CT to see early immunotherapy response in solid tumors and blood cancers

  We are testing if the 18F-G1 PET/CT scan can help tell early on whether people with solid tumors or blood cancers will respond to immunotherapy.

  Recruiting Peking University First Hospital · Beijing · NCT07039474

• Doxycycline added to standard treatment for central nervous system tuberculosis

  This trial tests whether adding doxycycline to standard anti‑TB therapy and corticosteroids helps adults with central nervous system tuberculosis live longer or have less severe neurological disability.

  Recruiting at 5 sites Phase 2 National University Hospital, Singapore · Medan, Medan and 5 other locations · NCT06446245

• Understanding immune cell behavior in sarcoidosis and tuberculosis

  This study is trying to understand how certain immune cells behave in people with sarcoidosis and tuberculosis to see what causes the ongoing inflammation in these conditions.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris · NCT05916638

• Evaluating a new method to measure tumor sugar consumption using PET imaging

  This study is testing a new way to measure how much sugar tumors use by comparing a new method with a standard scan in people with cancer.

  Recruiting Academisch Ziekenhuis Maastricht · Maastricht, Limburg · NCT05654675

• A network for collaborative cancer research in Ontario

  This study is testing a new way to improve cancer treatment by using genetics and technology to help personalize care for people with different types of cancer.

  Recruiting at 2 sites University Health Network, Toronto · Kingston, Ontario and 2 other locations · NCT05403177

• Validation of a blood test for early cancer detection and monitoring

  This study is testing a blood test to see if it can help find different types of cancer early and monitor patients after treatment.

  Recruiting at 3 sites Adela, Inc · Duarte, California and 16 other locations · NCT05366881

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.